Invizius

About

Invizius is a clinical-stage biotechnology company based in Edinburgh, Scotland, founded in 2018. The company specializes in second-generation complement therapeutics aimed at treating inflammatory, fibrotic, and autoimmune disorders, with a particular emphasis on improving outcomes for patients undergoing dialysis and other extracorporeal therapies. The company's lead product, H-Guard, is an anti-inflammatory coating designed for dialysis filters and extracorporeal circuits. This innovative coating helps reduce complement activation and inflammation, enhancing patient safety and clinical efficacy. Invizius's technology is rooted in research from the University of Edinburgh, focusing on harnessing natural complement regulators to address unmet medical needs in extracorporeal treatments. The company is actively engaged in developing its pipeline of complement therapeutics to benefit patients with various health conditions.